Get the latest Silexion Therapeutics Corp (SLXN) stock news and headlines to help you in your trading and investing decisions.

Company’s New Groundbreaking Preclinical Data in NSCLC Models Provides Further Validation for SIL204's Innovative Delivery ...

Silexion Therapeutics reports positive preclinical results for SIL204 in lung cancer, advancing dual-route administration and preparing for upcoming clinical trials.

Silexion Therapeutics is a pioneering clinical-stage, oncology-focused biotechnology company developing innovative RNA interference (RNAi) therapies to treat solid tumors driven by KRAS mutations ...

Silexion Therapeutics will present its KRAS-targeting RNAi therapy at the 2025 ASCO Gastrointestinal Cancers Symposium in January.

Silexion Therapeutics (NASDAQ: SLXN) is a pioneering clinical-stage, oncology-focused biotechnology company developing innovative RNA interference (RNAi) therapies to treat solid tumors driven by ...

About Silexion Therapeutics Silexion Therapeutics is a pioneering clinical-stage, oncology-focused biotechnology company developing innovative RNA interference (RNAi) therapies to treat solid ...

In addition to these structural changes, Silexion Therapeutics Corp has made significant progress in its preclinical studies for SIL-204, a siRNA candidate aimed at treating KRAS-driven cancers.